This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Stem Cell Therapy Market In Asia-Pacific To 2018 - Commercialization Supported By Favorable Government Policies, Strong Pipeline And Increased Licensing Activity

NEW YORK, April 24, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

http://www.reportlinker.com/p01075729/Stem-Cell-Therapy-Market-in-Asia-Pacific-to-2018---Commercialization-Supported-by-Favorable-Government-Policies-Strong-Pipeline-and-Increased-Licensing-Activity.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity SummaryGBI Research, the leading business intelligence provider, has released its latest research "Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity". The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals' JR-031 (2014) in Japan and FCB Pharmicell's Cerecellgram (CCG) (2015) in South Korea. The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. Stem cell research is dominated by hospitals/universities/institutions, which contribute 63% of the molecules in the pipeline. The dominance of institutional research is attributable to uncertain therapeutic outcomes in stem cell research.The major companies conducting research in India include Reliance Life Sciences and Stempeutics Research Pvt Ltd, among others. The major institutions include PGIMER and AIIMS. Scope- Country analysis of regulatory framework of India, China, South-Korea, Japan and Singapore- In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers. - Market characterization data for stem cell research for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. - Key drivers and restraints that have a significant impact on the market.- Competitive landscape of stem cell research in Asia-Pacific. The key companies discussed in this report are Stempeutics, Reliance Lifesciences, International Stem cell services, Shenzhen Beike Biotechnology, JCR Pharmaceuticals, ES Cells International, Stem Cell Technologies i, Pharmicell and Medipost- Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2007 till date. Reasons to buy- Build effective strategies to launch pipeline products by identifying the latest regulatory developments in the leading geographies- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth - Exploit in-licensing and out-licensing opportunities by identifying products that could fill their portfolio gaps - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships- Develop key strategic initiatives by studying the key strategies of top competitors- Reinforce R&D pipelines by identifying licensing strategies for acquiring new delivery mechanisms that have more efficiency and better safety

1 Table of Contents1 Table of Contents 51.1 List of Tables 81.2 List of Figures 102 Stem Cell Therapy Market in Asia-Pacific to 2018 - Introduction 133 Stem Cell Therapy Market in Asia-Pacific to 2018 - Overview 143.1 Introduction 143.2 Market Characterization and Forecasts - Overview 153.2.1 Revenue Forecasts 153.2.2 Cost of Therapy 163.2.3 Allogeneic and Autologous Share 173.2.4 Stem Cell Therapy Patient Pool 183.3 Drivers and Barriers 193.3.1 Drivers 203.3.2 Barriers 204 Stem Cell Therapy Market in Asia-Pacific to 2018 - India 214.1 Introduction 214.2 Regulatory Landscape 214.3 Market Characterization and Forecasts - Overview 224.3.1 Revenue Forecasts 224.3.2 Cost of Therapy 234.3.3 Stem Cell Patient Pool 234.4 CABG Market Characterization and Forecasts 244.4.1 Introduction 244.4.2 Revenue Forecasts 244.4.3 Cost of Therapy 254.4.4 Stem Cell Patient Pool 264.5 Type 2 DM Market Characterization and Forecasts 274.5.1 Introduction 274.5.2 Revenue Forecasts 284.5.3 Cost of Therapy 294.5.4 Stem Cell Patient Pool 304.6 LSCT Market Characterization and Forecasts 314.6.1 Introduction 314.6.2 Revenue Forecasts 314.6.3 Cost of Therapy 324.6.4 Stem Cell Patient Pool 335 Stem Cell Therapy Market in Asia-Pacific to 2018 - China 345.1 Introduction 345.2 Regulatory Landscape 345.3 Market Characterization and Forecasts - Overview 355.3.1 Type 1 DM Market Characterization and Forecasts 356 Stem Cell Therapy Market in Asia-Pacific to 2018 - Japan 396.1 Introduction 396.2 Regulatory Landscape 396.3 Steroid Refractory aGvHD Market Characterization and Forecasts 416.3.1 Overview 416.3.2 Revenue Forecasts 426.3.3 Cost of Therapy 436.3.4 Stem Cell Patient Pool 447 Stem Cell Therapy Market in Asia-Pacific to 2018 - Singapore 457.1 Introduction 457.2 Regulatory Landscape 457.2.1 Ethical, Legal and Social Issues in Human Stem Cell Research, Reproductive and Therapeutic Cloning ( June 2002) 467.2.2 Human Tissue Research ( November 2002) 477.2.3 Research Involving Human Subjects ( November 2004) 487.2.4 Genetic Testing and Genetic Research ( November 2005) 497.2.5 Personal Information in Biomedical Research ( May 2007) 507.2.6 Donation of Human Eggs for Research ( November 2008) 507.2.7 Human-Animal Combinations in Stem Cell Research ( September 2010) 508 Stem Cell Therapy Market in Asia-Pacific to 2018 - South Korea 518.1 Introduction 518.2 Regulatory Landscape 518.3 Market Characterization and Forecasts - Overview 538.3.1 Revenue Forecasts 538.3.2 Cost of Therapy 558.3.3 Stem Cell Patient Pool 568.4 Cupistem Market Characterization and Forecasts 578.4.1 Overview 578.4.2 Revenue Forecasts 588.4.3 Cost of Therapy 598.4.4 Stem Cell Patient Pool 608.5 HCG-AMI Market Characterization and Forecasts 618.5.1 Overview 618.5.2 Revenue Forecasts 628.5.3 Cost of Therapy 638.5.4 Stem Cell Patient Pool 648.6 Cartistem Market Characterization and Forecasts 658.6.1 Overview 658.6.2 Revenue Forecasts 668.6.3 Cost of Therapy 678.6.4 Stem Cell Patient Pool 688.7 CCG Market Characterization and Forecasts 698.7.1 Overview 698.7.2 Revenue Forecasts 698.7.3 Cost of Therapy 708.7.4 Stem Cell Patient Pool 719 Stem Cell Therapy Market in Asia-Pacific to 2018 - Pipeline Analysis 729.1 Pipeline Analysis by Phase 729.2 Pipeline Analysis by Sponsors/Collaborators 739.3 Pipeline Analysis by Country 749.3.1 India Stem Cell R&D Pipeline 759.3.2 China Stem Cell R&D Pipeline 779.3.3 Japan Stem Cell R&D Pipeline 819.3.4 Singapore Stem Cell R&D Pipeline 859.3.5 South Korea Stem Cell R&D Pipeline 869.3.6 Product Profiles of Promising Molecules 889.3.7 Product Profiles of Marketed Products 8910 Stem Cell Therapy Market in Asia-Pacific to 2018 - Competitive Landscape 9110.1 Stempeutics Research 9110.1.1 Overview 9110.1.2 Product Pipeline 9210.2 Reliance Life Sciences 9310.2.1 Overview 9310.2.2 Product Pipeline 9310.3 International Stem Cell Services 9410.3.1 Overview 9410.3.2 Product Pipeline 9410.4 Shenzhen Beike Biotechnology 9510.4.1 Overview 9510.4.2 Product Pipeline 9510.5 JCR Pharmaceuticals 9610.5.1 Overview 9610.5.2 Product Pipeline 9610.6 ES Cells International (Subsidiary of BioTime, Inc) 9710.6.1 Overview 9710.6.2 Product Pipeline 9710.7 Stem Cell Technologies i 9810.7.1 Overview 9810.7.2 Product Pipeline 9810.8 Pharmicell 9910.8.1 Overview 9910.8.2 Product Pipeline 9910.9 Medipost 10010.9.1 Overview 10010.9.2 Product Pipeline 10011 Stem Cell Therapy Market in Asia-Pacific to 2018 - Strategic Consolidations 10111.1 Overview 10111.2 M&A Deals 10211.2.1 RNL BIO Acquired 10% Stake in Celltex Therapeutics for $10m - October 28, 2011 10211.2.2 BioTime Acquired ES Cell International - May 3, 2010 10211.2.3 BCCL Acquires Stake in Life Cell - May 1, 2007 10211.3 Licensing Deals 10211.3.1 RNL BIO Forms Joint Venture to Develop Stem Cell Therapy - September 29, 2011 10211.3.2 Kiadis Pharma Enters into Licensing Agreement with Hospira for ATIR - January 4, 2011 10211.3.3 Cipla Enters into Co-Marketing Agreement with Stempeutics - April 27, 2010 10211.3.4 Teijin Enters into Licensing Agreement with SanBio - March 2, 2010 10211.3.5 Cleveland BioLabs Enters into Licensing Agreement with Zhejiang Hisun Pharma - September 9, 2009 10311.3.6 Merck Signs a Licensing Agreement with Japan Tobacco - September 25, 2008 10311.3.7 ES Cell Enters into Licensing Agreement with ITI Life Sciences - January 31, 2007 10311.4 Co-Development Deals 10311.4.1 JCR Pharma Enters into Co-Development Agreement with MediPal - September 13, 2011 10311.4.2 Athersys Enters into Co-Development Agreement with Pfizer - December 21, 2009 10311.4.3 Genzyme Enters into Agreement with Osiris Therapeutics - November 4, 2008 10411.4.4 JCR Pharma Enters into Co-Development Agreement with Mochida Pharma - December 21, 2007 10412 Stem Cell Therapy Market in Asia-Pacific to 2018 - Appendix 10512.1 Market Definitions 10512.2 Abbreviations 10512.3 Bibliography 10712.4 Research Methodology 10812.4.1 Coverage 10812.4.2 Secondary Research 10812.4.3 Primary Research 10912.5 Therapeutic Landscape 10912.5.2 Market Size by Geography 11112.6 Geographical Landscape 11212.7 Pipeline Analysis 11212.8 Competitive Landscape 11212.8.1 Expert Panel Validation 11212.9 Contact Us 11212.10 Disclaimer 112 List of Tables1.1 List of TablesTable 1: Stem Cell Therapy Market in Asia-Pacific to 2018, Revenue Forecasts ($m), 2012-2018 15Table 2: Stem Cell Therapy Market in Asia-Pacific to 2018, Patient Pool for Stem Cell Therapy Forecasts ('000), 2012-2018 18Table 3: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Revenue Forecasts ($m), 2012-2018 22Table 4: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Patient Pool Forecasts ('000), 2012-2018 23Table 5: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Revenue Forecasts ($'000), 2012-2018 24Table 6: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Cost of Therapy Forecasts ($), 2012-2018 25Table 7: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Patient Pool Forecasts (Absolute), 2012-2018 26Table 8: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Revenue Forecasts ($m), 2012-2018 28Table 9: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Cost of Therapy Forecasts ($), 2012-2018 29Table 10: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Patient Pool Forecasts ('000), 2012-2018 30Table 11: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Revenue Forecasts ($'000), 2012-2018 31Table 12: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Cost of Therapy Forecasts ($), 2012-2018 32Table 13: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Patient Pool Forecasts (Absolute), 2012-2018 33Table 14: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Revenue Forecasts ($m), 2012-2018 36Table 15: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Cost of Therapy Forecasts ($), 2012-2018 37Table 16: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Patient Pool Forecasts ('000), 2012-2018 38Table 17: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Revenue Forecasts ($m), 2014-2018 42Table 18: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Cost of Therapy Forecasts ($), 2014-2018 43Table 19: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Patient Pool for Stem Cell Therapy Forecasts (Absolute), 2014-2018 44Table 20: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Revenue Forecasts ($m), 2012-2018 53Table 21: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Patient Pool for Stem Cell Therapy, Forecasts (Absolute), 2012-2018 56Table 22: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Revenue Forecasts ($m), 2012-2018 58Table 23: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Cost of Therapy Forecasts ($), 2012-2018 59Table 24: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Patient Pool Forecasts (Absolute), 2012-2018 60Table 25: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Revenue Forecasts ($m), 2012-2018 62Table 26: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Cost of Therapy Forecasts ($), 2012-2018 63Table 27: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Patient Forecasts, 2012-2018 64Table 28: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Revenue Forecasts ($m), 2012-2018 66Table 29: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Cost of Therapy Forecasts ($), 2012-2018 67Table 30: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Patient Pool Forecasts (Absolute), 2012-2018 68Table 31: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Revenue Forecasts ($m), 2015-2018 69Table 32: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Cost of Therapy Forecasts ($), 2015-2018 70Table 33: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Patient Pool Forecasts (Absolute), 2015-2018 71Table 34: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Phase, 2012 72Table 35: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Sponsors/Collaborators, 2012 73Table 36: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Country, 2012 74Table 37: Stem Cell Therapy Market in Asia-Pacific to 2018, India, R&D Pipeline Analysis by Phase, 2012 75Table 38: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase II/III Pipeline Analysis, 2012 76Table 39: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase II Pipeline Analysis, 2012 76Table 40: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase I/II Pipeline Analysis, 2012 76Table 41: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Unknown Phase, 2012 76Table 42: Stem Cell Therapy Market in Asia-Pacific to 2018, China, R&D Pipeline Analysis by Phase, 2012 77Table 43: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Post-Market Pipeline Analysis, 2012 78Table 44: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase II Pipeline Analysis, 2012 78Table 45: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase I/II Pipeline Analysis, 2012 79Table 46: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase I Pipeline Analysis, 2012 79Table 47: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Clinical Pre-Test Pipeline Analysis, 2012 80Table 48: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Unknown Phase, 2012 80Table 49: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, R&D Pipeline Analysis by Phase, 2012 81Table 50: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase III Stage Molecules Pipeline Analysis, 2012 82Table 51: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase II/III Stage Molecules Pipeline Analysis, 2012 82Table 52: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase II Stage Molecules Pipeline Analysis, 2012 83Table 53: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase I/II Stage Molecules Pipeline Analysis, 2012 84Table 54: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase I Stage Molecules Pipeline Analysis, 2012 84Table 55: Stem Cell Therapy Market in Asia-Pacific to 2018, Singapore, Phase I/II Stage Molecules Pipeline Analysis, 2012 85Table 56: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, R&D Pipeline Analysis by Phase, 2012 86Table 57: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase III Molecules Pipeline Analysis, 2012 87Table 58: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase II/III Molecules Pipeline Analysis, 2012 87Table 59: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase II Molecules Pipeline Analysis, 2012 87Table 60: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase I/II Molecules Pipeline Analysis, 2012 87Table 61: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase I Molecules Pipeline Analysis, 2012 88Table 62: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Unknown Phase, 2012 88Table 63: Stem Cell Therapy Market in Asia-Pacific to 2018, Stempeutics, R&D Pipeline, 2012 92Table 64: Stem Cell Therapy Market in Asia-Pacific to 2018, Reliance Life Sciences, R&D Pipeline, 2012 93Table 65: Stem Cell Therapy Market in Asia-Pacific to 2018, International Stem Cell Services Limited, R&D Pipeline, 2012 94Table 66: Stem Cell Therapy Market in Asia-Pacific to 2018, Shenzhen Beike Biotechnology R&D Pipeline, 2012 95Table 67: Stem Cell Therapy Market in Asia-Pacific to 2018, JCR Pharmaceuticals Co. Ltd, R&D Pipeline, 2012 96Table 68: Stem Cell Therapy Market in Asia-Pacific to 2018, Pharmicell, R&D Pipeline, 2012 99Table 69: Stem Cell Therapy Market in Asia-Pacific to 2018, Medipost, R&D Pipeline, 2012 100Table 70: Stem Cell Therapy Market in Asia-Pacific to 2018, Strategic Consolidations Overview, 2007-2012 101 List of Figures1.2 List of FiguresFigure 1: Stem Cell Therapy Market in Asia-Pacific to 2018, Overview, 2012 14Figure 2: Stem Cell Therapy Market in Asia-Pacific to 2018, Revenue Forecasts ($m), 2012-2018 15Figure 3: Stem Cell Therapy Market in Asia-Pacific to 2018, Cost of Therapy Overview ($), 2012 16Figure 4: Stem Cell Therapy Market in Asia-Pacific to 2018, Allogeneic vs. Autologous (%), 2012 17Figure 5: Stem Cell Therapy Market in Asia-Pacific to 2018, Patient Pool for Stem Cell Therapy Forecasts ('000), 2012-2018 18Figure 6: Stem Cell Therapy Market in Asia-Pacific to 2018, Drivers and Barriers, 2012 19Figure 7: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Revenue Forecasts ($m), 2012-2018 22Figure 8: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Cost of Therapy Overview ($), 2012 23Figure 9: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Patient Pool Forecasts ('000), 2012-2018 23Figure 10: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Revenue Forecasts ($'000), 2012-2018 24Figure 11: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Cost of Therapy Forecasts ($), 2012-2018 25Figure 12: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Patient Pool Forecasts (Absolute), 2012-2018 26Figure 13: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Revenue Forecasts ($m), 2012-2018 28Figure 14: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Cost of Therapy Forecasts ($), 2012-2018 29Figure 15: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Patient Pool Forecasts ('000), 2012-2018 30Figure 16: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Revenue Forecasts ($'000), 2012-2018 31Figure 17: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Cost of Therapy Forecasts ($), 2012-2018 32Figure 18: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Patient Pool Forecasts (Absolute), 2012-2018 33Figure 19: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Regulatory Framework Timeline, 1998-2009 34Figure 20: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Revenue Forecasts ($m), 2012-2018 36Figure 21: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Cost of Therapy Forecasts ($), 2012-2018 37Figure 22: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Patient Pool Forecasts ('000), 2012-2018 38Figure 23: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, MHLW Stem Cell Guidelines, 2010 39Figure 24: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, JR-031 Overview, 2012 41Figure 25: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Revenue Forecasts ($m), 2014-2018 42Figure 26: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Cost of Therapy Forecasts ($), 2014-2018 43Figure 27: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Patient Pool for Stem Cell Therapy Forecasts (Absolute), 2014-2018 44Figure 28: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Stem Cell Therapeutics Approval Process, 2011 51Figure 29: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Biopharmaceutical Implementation Strategies, 2011 52Figure 30: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Revenue Forecasts ($m), 2012-2018 53Figure 31: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Autologous and Allogeneic Share (%), 2012 54Figure 32: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Marketed Products Share (%), 2012 and 2018 54Figure 33: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cost of Therapy ($), Overview, 2012 55Figure 34: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Patient Pool for Stem Cell Therapy, Forecasts (Absolute), 2012-2018 56Figure 35: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Revenue Forecasts ($m), 2012-2018 58Figure 36: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Cost of Therapy Forecasts ($), 2012-2018 59Figure 37: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Patient Pool Forecasts (Absolute), 2012-2018 60Figure 38: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Revenue Forecasts ($m), 2012-2018 62Figure 39: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Cost of Therapy Forecasts ($), 2012-2018 63Figure 40: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Patient Forecasts (Absolute), 2012-2018 64Figure 41: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Revenue Forecasts ($m), 2012-2018 66Figure 42: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Cost of Therapy Forecasts ($), 2012-2018 67Figure 43: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Patient Pool Forecasts (Absolute), 2012-2018 68Figure 44: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Revenue Forecasts ($m), 2015-2018 69Figure 45: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Cost of Therapy Forecasts ($), 2015-2018 70Figure 46: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Patient Pool Forecasts (Absolute), 2015-2018 71Figure 47: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Phase (%), 2012 72Figure 48: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Sponsors/Collaborators (%), 2012 73Figure 49: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Country (%), 2012 74Figure 50: Stem Cell Therapy Market in Asia-Pacific to 2018, India, R&D Pipeline Analysis by Phase (%), 2012 75Figure 51: Stem Cell Therapy Market in Asia-Pacific to 2018, China, R&D Pipeline Analysis by Phase (%), 2012 77Figure 52: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, R&D Pipeline Analysis by Phase (%), 2012 81Figure 53: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, R&D Pipeline Analysis by Phase (%), 2012 86Figure 54: Stem Cell Therapy Market in Asia-Pacific to 2018, Stempeutics, Overview, 2012 91Figure 55: Stem Cell Therapy Market in Asia-Pacific to 2018, Reliance Life Sciences, Overview, 2012 93Figure 56: Stem Cell Therapy Market in Asia-Pacific to 2018, International Stem Cell Services, Overview, 2012 94Figure 57: Stem Cell Therapy Market in Asia-Pacific to 2018, Shenzhen Beike Biotechnology Overview, 2012 95Figure 58: Stem Cell Therapy Market in Asia-Pacific to 2018, JCR Pharmaceuticals Overview, 2012 96Figure 59: Stem Cell Therapy Market in Asia-Pacific to 2018, ES Cells International, Overview, 2012 97Figure 60: Stem Cell Therapy Market in Asia-Pacific to 2018, Stem Cell Technologies i, Overview, 2012 98Figure 61: Stem Cell Therapy Market in Asia-Pacific to 2018, Pharmicell Overview, 2012 99Figure 62: Stem Cell Therapy Market in Asia-Pacific to 2018, Medipost, Overview, 2012 100Figure 63: Stem Cell Therapy Market in Asia-Pacific to 2018, Strategic Consolidations Overview (%), 2007-2012 101Figure 64: GBI Research Market Forecasting Model 111 Companies MentionedStempeutics ResearchReliance Life SciencesInternational Stem Cell ServicesShenzhen Beike BiotechnologyJCR PharmaceuticalsES Cells International (Subsidiary of BioTime, Inc)Stem Cell Technologies iPharmicell Medipost

To order this report: Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs